CHELSEA THERAPEUTICS INTERNATIONAL LTD | 1,696 Euro | -0,041 -2,36 % | |
| WKN: A0JJXQ ISIN: US1634281059 Ticker-Symbol: 3CH | Frankfurt | 20.06.13 | 09:01 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 17.06. | Chelsea Therapeutics International: 52-Week High Recently Eclipsed | 6 | SmarTrend | |
| 17.06. | Chelsea Therapeutics International Up 10.2%, Shares Break Through Resistance | 2 | SmarTrend | |
| 11.06. | Chelsea Therapeutics International, Ltd. - 8-K, Current Report | 5 | SEC Filings | |
| 06.06. | Hot Stock: Chelsea Therapeutics International, Shares Gain 5.3% | 11 | SmarTrend | |
| 31.05. | Chelsea Therapeutics International's Management Presents at 38th Annual dbAccess Health Care Conference (Transcript) | 3 | Seeking Alpha | |
| 02.05. | Chelsea Therapeutics trims loss in 1Q | 8 | bizjournals | |
| 20.04. | Lead Counsel in Securities Class Action Against Chelsea Therapeutics International Ltd. Announces Court Hearing | 174 | PR Newswire | |
| NEW YORK, April 19, 2013 /PRNewswire/ --Lead Counsel Faruqi & Faruqi, LLP announces that the United States District Court for the Western District of North Carolina has scheduled a hearing on the... Mehr lesen zu: Lead Counsel in Securities Class Action Against Chelsea Therapeutics International Ltd. Announces Court Hearing | ||||
| 19.04. | Chelsea Therapeutics International, Ltd. - 8-K, Departure of Directors or Certain Officers; ... | 5 | SEC Filings | |
| 12.04. | Possible Bearish Inside Day Candle Pattern Detected for Chelsea Therapeutics International | 5 | SmarTrend | |
| 08.04. | Is Chelsea Therapeutics A Buy After Skyrocketing Up Over 150%? | 14 | Seeking Alpha | |
| 08.04. | Pre-Market Analysis on Sarepta Therapeutics, BioMarin Pharma, Theravance, and Chelsea Therapeutics | 65 | PR Newswire | |
| LONDON, April 8, 2013 /PRNewswire/ --
The U.S. Supreme Court, last year, upheld President Obama's Affordable Care Act (ACA). The ACA is expected to have a significant impact on the biotechnology... Mehr lesen zu: Pre-Market Analysis on Sarepta Therapeutics, BioMarin Pharma, Theravance, and Chelsea Therapeutics | ||||
| 27.03. | Stock to Watch: Chelsea Therapeutics International Up 10.0% | 5 | SmarTrend | |
| 27.03. | Chelsea Therapeutics: A Shoe-In For FDA Approval, Shares Could Double From Here | 12 | Seeking Alpha | |
| 14.03. | Chelsea Therapeutics International, Ltd. - 10-K/A, Annual Report | 8 | SEC Filings | |
| 07.03. | BioMarin Pharma, Amgen, Sarepta Therapeutics, Chelsea Therapeutics Intl., and Theravance Early Briefing and Review | 92 | PR Newswire | |
| LONDON, March 7, 2013 /PRNewswire/ --
Markets inched up higher yesterday after hitting all time highs earlier this week. The healthcare sector also showed promise as the the sector's stocks moved... Mehr lesen zu: BioMarin Pharma, Amgen, Sarepta Therapeutics, Chelsea Therapeutics Intl., and Theravance Early Briefing and Review | ||||
| 26.02. | Possible Bullish Inside Day Candle Pattern Detected for Chelsea Therapeutics International | 5 | SmarTrend | |
| 21.02. | Upgrade Alert for Chelsea Therapeutics International | 21 | SmarTrend | |
| 21.02. | Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High / RDInvesting Provides Stocks Research on Chelsea Therapeutics and Cyclacel Pharmaceuticals | 80 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 02/21/13 -- A sharp increase in drug approvals and mergers and acquisitions combined to create a bull market for the Biotechnology Industry in 2012. The iShares NASDAQ... Mehr lesen zu: Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High / RDInvesting Provides Stocks Research on Chelsea Therapeutics and Cyclacel Pharmaceuticals | ||||
| 20.02. | Chelsea Therapeutics Back on the Map in a Serious Way | 16 | DailyFinance | |
| 20.02. | Chelsea Therapeutics International's CEO Discusses Chelsea Therapeutics Receives FDA Guidance for Northera (TM) (Droxidopa) NDA Resubmission With Study 306B Conference (Transcript) | 10 | Seeking Alpha | |
Seite: 1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| ARENA PHARMACEUTICALS | 5,719 | -0,52 % | Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference |
| BIOSANTE PHARMACEUTICALS | 0,92 | -2,65 % | BioSante Recommends Stockholders Vote For Proposed Merger With ANI Pharma |
| SUNESIS PHARMACEUTICALS | 3,78 | +1,56 % | Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial With no Change to Study Conduct |
| SPECTRUM PHARMACEUTICALS | 6,108 | -0,16 % | Spectrum Pharmaceuticals Has Returned 26.6% Since SmarTrend Recommendation |
| CATALYST PHARMACEUTICAL PARTNERS | 0,689 | -3,37 % | CATALYST PHARMACEUTICAL PARTNERS, INC. - 8-K, Current Report |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von